Categories
Anticancer Drugs Bortezomib Medicine Oncology Pharmacology Physiotherapy

Bortezomib

In this article we will discuss about Bortezomib (Dosage Overview)

In this article, we will discuss about Bortezomib (Dosage Overview). So, let’s get started.

Indications

Bortezomib for injection is a proteasome inhibitor indicated for:
– treatment of patients with multiple myeloma.
– treatment of patients with mantle cell lymphoma who have received at least 1 prior therapy.

Dosage

– For intravenous use only. Exercise caution when calculating the volume to be administered.
– The recommended starting dose of bortezomib for injection is 1.3 mg/m² administered as a 3 to 5 second bolus intravenous injection.
– Hepatic Impairment: Use a lower starting dose for patients with moderate or severe hepatic impairment.
– Dose must be individualized to prevent overdose.

Warnings and Precautions

• Peripheral Neuropathy: Manage with dose modification or discontinuation. Patients with pre-existing severe neuropathy should be treated with bortezomib for injection only after careful
risk-benefit assessment.
• Hypotension: Use caution when treating patients taking anti hypertensives, with a history of syncope, or with dehydration.
• Cardiac Toxicity: Worsening of and development of cardiac failure has
occurred. Closely monitor patients with existing heart disease or risk factors for heart disease.
• Pulmonary Toxicity: Acute respiratory syndromes have occurred. Monitor closely for new or worsening symptoms.
• Posterior Reversible Encephalopathy Syndrome: Consider MRI imaging
for onset of visual or neurological symptoms; discontinue bortezomib if
suspected.
• Gastrointestinal Toxicity: Nausea, diahea, constipation, and vomiting may require use of antiemetic and antidiarrheal medications or fluid replacement.
• Thrombocytopenia or Neutropenia: Monitor complete blood counts regularly throughout treatment.
• Tumor Lysis Syndrome: Closely monitor patients with high tumor burden.
• Hepatic Toxicity Monitor hepatic enzymes during treutment.
• Embryo-fetal Toxicity: Bortezomib can cause fetal harm. Advise females
of reproductave potential of the potential risk to a fetus and to avoid pregnancy.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.